PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...
A phase 2 study has suggested that the glycoprotein (gp) IIb/IIIa blocker eptifibatide can be safely combined with a reduced dose of tPA in the treatment of acute ischemic stroke, and there was a ...
Administering intra-arterial tissue plasminogen activator (tPA; alteplase) after successful thrombectomy boosts outcomes in patients with acute ischemic strokes caused by large-vessel occlusions, the ...
Among patients presenting directly to a thrombectomy-equipped center with a large-vessel ischemic stroke, going directly to the endovascular suite and forgoing initial IV thrombolytic therapy provides ...
(HealthDay News) — Blacks, Hispanics, women, seniors on Medicare, and patients in rural areas are less likely to be treated with tissue plasminogen activator (tPA) after stroke, according to research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback